10-K: Salarius Pharmaceuticals Faces Going Concern Uncertainty Amidst Proposed Merger with Decoy Therapeutics

Salarius Pharmaceuticals reports a net loss for 2024 and expresses substantial doubt about its ability to continue as a going concern, while pursuing a merger with Decoy Therapeutics to address its financial challenges.

Summary

• Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company, is facing significant financial challenges, reporting a net loss of $5.58 million for the year ended December 31, 2024, and an accumulated deficit of $81.9 million.
• The company's cash and cash equivalents totaled $2.4 million as of December 31, 2024, which is believed to be sufficient to fund operations into the later part of the second quarter of 2025.
• Salarius has curtailed expenses and plans to use its two remaining full time employees and consultants to continue its operations.
• The company has entered into a merger agreement with Decoy Therapeutics, Inc., a stock-for-stock transaction where Decoy stockholders would own approximately 85.9% of Salarius after the merger, subject to adjustments and a Qualified Financing.
• The merger is contingent upon securing minimum proceeds of $6.0 million through future offerings and maintaining Salarius' listing on Nasdaq.
• If the merger is not completed, Salarius may need to dissolve and liquidate its assets, leaving uncertainty about the amount, if any, available for distribution to stockholders.
• Salarius' common stock is at risk of being delisted from Nasdaq due to non-compliance with the Stockholders Equity Requirement.
• The company's strategic focus remains on developing treatments for cancers caused by dysregulated gene expression, with two small molecule drugs in its pipeline: SP-3164 and seclidemstat (SP-2577).
• Salarius has discontinued its ongoing Phase 1/2 clinical trial evaluating SP-2577 for Ewing sarcoma to conserve cash, but continues to support an investigator-initiated clinical trial at MD Anderson Cancer Center.
• The company is dependent on its remaining employees and consultants to facilitate the merger and maintain operations.
• Salarius is subject to numerous risks, including those related to the merger, its financial position, product development, regulatory approval, and intellectual property.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation for Salarius, with a going concern warning and reliance on a merger for survival. While the merger offers potential, the risks and uncertainties outweigh the positives, resulting in a low sentiment score.

Positives

• Salarius is actively pursuing a merger with Decoy Therapeutics, which could provide a path forward and address its financial challenges.
• The company continues to support an investigator-initiated clinical trial at MD Anderson Cancer Center evaluating SP-2577.
• Salarius has implemented cost-saving measures to extend its expected cash runway into the later part of the second quarter of 2025.
• The partial clinical hold on the MDACC sponsored clinical trial evaluating SP-2577 has been lifted, with patient enrollment resuming in the trial.

Negatives

• Salarius faces substantial doubt about its ability to continue as a going concern.
• The company has incurred significant operating losses and has an accumulated deficit of $81.9 million.
• Salarius has discontinued its ongoing Phase 1/2 clinical trial evaluating SP-2577 for Ewing sarcoma to conserve cash.
• The company's common stock is at risk of being delisted from Nasdaq.
• The merger with Decoy Therapeutics is subject to several conditions and may not be completed.
• Salarius is substantially dependent on its remaining employees and consultants to facilitate the consummation of the Merger.

Risks

• The merger with Decoy Therapeutics may not be completed, and if it is, it may not enhance stockholder value.
• Salarius may not be able to source adequate liquidity to fund its operations if the merger is not completed.
• The company's common stock may be subject to delisting from Nasdaq.
• Salarius is substantially dependent on its remaining employees and consultants to facilitate the consummation of the Merger.
• The company has never generated any revenue from product sales and may never generate revenue or be profitable.
• Clinical trials are costly, time consuming and inherently risky, and may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
• Salarius may not be successful in obtaining or maintaining necessary rights to Salarius targets, product compounds and processes for Salarius development pipeline through acquisitions and in-licenses.
• Third-party claims of intellectual property infringement may prevent or delay Salarius development and commercialization efforts.

Future Outlook

Salarius believes its existing cash resources are sufficient to meet its anticipated needs into the later part of the second quarter of 2025, but will need to raise additional capital to continue to fund the further development of its product candidates and its operations thereafter.

Industry Context

The biopharmaceutical industry is characterized by high risk and uncertainty, particularly for clinical-stage companies like Salarius. The company's focus on epigenetic enzyme technology aligns with emerging trends in targeted cancer therapies, but also faces competition from larger pharmaceutical companies.

Comparison to Industry Standards

• Given the lack of revenue and the stage of development, Salarius is comparable to other clinical-stage biopharmaceutical companies such as Kura Oncology, Inc. and Constellation Pharmaceuticals, Inc. before its acquisition by MorphoSys AG.
• These companies often rely on venture capital, strategic partnerships, and public offerings to fund their research and development activities.
• The success of these companies depends on the clinical trial results, regulatory approvals, and commercialization of their product candidates.
• Salarius' financial position and future prospects are heavily influenced by the outcome of its merger with Decoy Therapeutics and its ability to secure additional funding.

Management Changes

Related Party Transactions

• Dr. McVicar, a member of the Salarius board of directors, serves as a consultant to DeuteRx and is a consultant to an affiliate of DeuteRx, which was party to the ASCA.

Stakeholder Impact

• Shareholders face significant risk of dilution and potential loss of investment.
• Employees face uncertainty regarding job security and the future of the company.
• Patients may experience delays in the development of new cancer treatments.
• Creditors face increased risk of non-payment.

Next Steps

• Complete the proposed merger with Decoy Therapeutics, Inc.
• Secure the Qualified Financing of at least $6.0 million.
• Obtain stockholder approval for the Conversion Proposal, Equity Plan Proposal, and Reverse Stock Split Proposal.
• Maintain compliance with Nasdaq listing requirements.
• Continue to support the investigator-initiated clinical trial at MD Anderson Cancer Center.

Key Dates

Keywords

Merger, Decoy Therapeutics, Going concern, Financial position, Clinical trials, SP-3164, SP-2577, Nasdaq, Delisting, Liquidity, Capital raise, Pharmaceuticals, Biopharmaceutical, Oncology